A Phase 1 Dose Escalation Trial of Third-Generation CD19-Directed CAR T-Cells Incorporating CD28 and Toll-like Receptor 2 (TLR2) Intracellular Domains for Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas (ENABLE)
Year: 2023
Type: conference-abstract
Source: Blood
Authors: Robert Weinkove, Philip George, Robert Fyfe, Nathaniel Dasyam, Yasmin Nouri, Tess Ostapowicz, Stefan Mullins, Brigitta Mester, Giulia Giunti, Catherine M. Bollard, Travis Perera, Hayden Jina, Alwyn D'Souza, Le Qin, David S. Ritchie, Chris M.A. Frampton, Rachel Perret, Peng Li, Ian Hermans
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4389220840